Pushing lower boundaries

GAITHERSBURG, Md.—Microdosing specialist Xceleron announced an agreement with Neurocrine Biosciences for a multi-arm Phase 0 study

Randall C Willis
GAITHERSBURG, Md.—Microdosing specialist Xceleron announced an agreement with Neurocrine Biosciences for a multi-arm Phase 0 study that will evaluate preliminary pharmacokinetics (PK) and metabolism of five compounds. Xceleron will conduct clinical trials in Europe with accelerator mass spectrometry analysis completed at the company's GLP accredited laboratories in York, U.K.
 
"Partnering with Xceleron to bring our drug candidates into clinical development early in the development process provides Neurocrine with significant benefits in terms of or additional candidate selection as well as reduced risk and cost," said Dr. Haig Bozigian, Neurocrine's vice president of preclinical development. "While our lead compound is being evaluated in clinical studies, microdose studies will provide additional valuable comparative pharmacokinetics and bioavailability for our back-up compounds."

Randall C Willis

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

November 2022 Issue Front Cover

Latest Issue  

• Volume 18 • Issue 11 • November 2022

November 2022

November 2022